key: cord-0986927-dq28lgr1
authors: Wilson, Patrick; Changrob, Siriruk; Fu, Yanbin; Guthmiller, Jenna; Halfmann, Peter; Li, Lei; Stamper, Christopher; Dugan, Haley; Accola, Molly; Rehrauer, William; Zheng, Nai-Ying; Huang, Min; Wang, Jiaolong; Erickson, Steven; Utset, Henry; Graves, Hortencia; Amanat, Fatima; Sather, D. Noah; Krammer, Florian; Kawaoka, Yoshihiro
title: Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike
date: 2021-07-19
journal: Res Sq
DOI: 10.21203/rs.3.rs-678247/v1
sha: 623160194312b51250b9744629fa3bb637612a7b
doc_id: 986927
cord_uid: dq28lgr1

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have arisen that exhibit increased viral transmissibility and partial evasion of immunity induced by natural infection and vaccination. To address the specific antibody targets that were affected by recent viral variants, we generated 43 monoclonal antibodies (mAbs) from 10 convalescent donors that bound three distinct domains of the SARS-CoV-2 spike. Viral variants harboring mutations at K417, E484 and N501 could escape most of the highly potent antibodies against the receptor binding domain (RBD). Despite this, we identified 12 neutralizing mAbs against three distinct regions of the spike protein that neutralize SARS-CoV-2 and the variants of concern, including B.1.1.7 (alpha), P.1 (gamma) and B.1.617.2 (delta). Notably, antibodies targeting distinct epitopes could neutralize discrete variants, suggesting different variants may have evolved to disrupt the binding of particular neutralizing antibody classes. These results underscore that humans exposed to wildtype (WT) SARS-CoV-2 do possess neutralizing antibodies against current variants and that it is critical to induce antibodies targeting multiple distinct epitopes of the spike that can neutralize emerging variants of concern.

The emergence of novel circulating SARS-CoV-2 variants of concern (VOCs) have recently proven to undermine the protective effects of infection-and vaccination-induced humoral immunity [1] [2] [3] [4] . All approved vaccines against SARS-CoV-2 drive a neutralizing antibody response against the spike protein, the major target of neutralizing antibodies elicited by natural infection 3, 5 . However, protective humoral immunity against the spike protein induced by vaccination or infection with the original wildtype (WT) virus may be attenuated due to the widespread circulation of variants 2 . The rst reported mutation of the SARS-CoV-2 spike protein, D614G, arose in the C-terminal domain (CTD) and evolved due to increased stability of the spike rather than a mutation to escape host immunity 6 . More recently, mutations have arisen within the receptor-binding domain (RBD), N-terminal domain (NTD) of S1, and S2 that have resulted in emergence of several circulating viral variants that are rapidly becoming the dominant strains around the globe 2 . The B.1.1.7 lineage or alpha VOC, rst found in the United Kingdom, has been reported to have a >50% increased transmissibility among humans [7] [8] [9] [10] . Of greatest concern is the substitution at position 484 in the RBD, which is exclusively shared by the VOCs and variants of interest (VOIs) originally identi ed in South Africa (B.1.351; beta), Brazil (P.1; gamma), Texas (R.1), New York (B.1.526; iota) and India (B.1.617.1; kappa) 2,3,11-15 . VOCs possessing a mutation at E484, either E484K and E484Q, can partially evade neutralizing humoral immunity induced by either natural infection or vaccination and, in rare cases, lead to reinfection and infection, respectively [11] [12] [13] [16] [17] [18] . Other emerging variants have acquired a mutation at L452R within the RBD, which is found in B. 1 15, 20 . The most recent VOC, B.1.617.2 (delta), is responsible for a surge in both cases and fatalities in several countries, especially where vaccination rates are low 4,21-23 . Intriguingly, the B.1.617 lineages contain P681R, a mutation that enhances and accelerates viral fusion 24 and which is also present in the dominant variant in Uganda, A.23.1 25 . Thus, understanding the impact of these various mutations on the neutralization capacity of antibodies elicited by current vaccine formulations or natural exposure to wildtype (WT) SARS-CoV-2 is urgently needed to lay the foundation for next-generation vaccine strategies against SARS-CoV-2 variants.

Here we report that natural WT SARS-CoV-2 infection induces memory B cells expressing potently neutralizing antibodies against VOCs. Moreover, natural WT infection largely induced antibodies against spike epitopes outside of the RBD, most of which were non-neutralizing against WT and VOCs. Additionally, RBD-binding antibodies could be categorized into 3 distinct classes based on their binding pro les against RBD mutant constructs. We identi ed VOC-neutralizing antibodies against three distinct regions of the spike protein, including the two epitopes on the RBD and one epitope in the NTD. Together, our study identi es that natural WT infection induces memory B cells that can produce neutralizing antibodies against recent SARS-CoV-2 VOCs and have the potential to be recalled by vaccination.

Convalescent sera have reduced antibody titers but retain neutralization capabilities against circulating SARS-CoV-2 VOCs

To investigate whether antibodies from subjects naturally infected with WT SARS-CoV-2 lost binding or neutralization activity against VOCs, we collected blood samples from 10 convalescent donors at a median of 49 days post-symptom onset 26, 27 (Supplementary Table 1 ) for in-depth analysis of speci city of individual memory B cells. As an initial estimate of antibody activity from these patients, serum antibody reactivity was measured comparing reactivity to WT trimeric SARS-CoV-2 spike and spike proteins from the D614G, B. (Fig. 1a) . Similarly, IgG titers against the RBD of B.1.1.7 (1.7-fold), B.1.351 (2.8-fold) and P.1 (2.6-fold) were reduced compared to WT RBD. However, we noted that there was less than a 2-fold decrease in antibody binding against single mutants of the RBD (Fig. 1b) . Despite reductions in serum binding activity, the sera retained similar neutralizing titers against the WT, B.1.1.7 and P.1 SARS-CoV-2 variants. However, we found a signi cant reduction in neutralization against B.1.617.1 and B.1.617.2 compared to WT (Fig. 1c) . Although antibody titers were lower against the VOCs, these data indicate that serum antibodies elicited by natural WT infection were able to neutralize B.1.1.7, P.1 and WT virus equally, while most donors lost neutralizing potential against B.1.617-lineage viruses.

Generation of mAbs against distinct domains of the SARS-CoV-2 spike We next sought to determine the speci cities of antibodies that could cross-neutralize these viral variants by generating mAbs from spike-binding B cells isolated from 10 convalescent subjects collected between April and July of 2020 26, 27 . We sort-puri ed B cells binding to spike and/or RBD uorophore-and oligoconjugated probes, and performed single-cell RNA-sequencing and B cell receptor sequencing. As the antigen probes included a DNA oligonucleotide sequence, we were able to track the antigen-speci city of isolated B cells. In total, we obtained 1,703 paired immunoglobulin heavy and light chains from non-RBDand RBD-binding B cells speci c for the spike. Overall, the percentage of spike non-RBD-binding B cells was 4-fold higher than RBD-binding B cells (Fig. 2a-c) , indicating that natural WT infection preferentially induced B cell response toward epitopes on the spike outside of the RBD 28, 29 Based on the acquired antibody sequences and probe-binding intensities, we generated 43 mAbs from all 10 donors speci c to the WT spike protein (Supplementary Table 2 ). To investigate speci c domain targeting, mAbs were tested for binding to the RBD and monomeric S1 and S2 recombinant spike antigens. Based on binding to these discrete antigens, spike-reactive mAbs were categorized into 4 groups: NTD-A-reactive mAbs (n=5) that bound strongly to S1 but not RBD, NTD-B-reactive mAbs (n=7) that weakly bind S1 but not RBD, S2-reactive mAbs (n=2), and RBD-reactive mAbs (n=29) (Fig. 2d-e) . Additionally, NTD-A and NTD-B-classi ed antibodies targeted distinct epitopes as shown by competition ELISA (Supplementary Figure 2a) . We further determined whether antibodies with different binding speci cities differ in their neutralization capacity against WT SARS-CoV-2. Of the 43 mAbs, 18 (42%) were neutralizing. Notably, only mAbs binding the RBD and NTD-B were neutralizing, whereas all mAbs binding NTD-A and S2 were non-neutralizing ( Fig. 2d-f ). Moreover, 52% of RBD-targeting mAbs were neutralizing, with eight mAbs being potently neutralizing antibodies (50% inhibitory concentration, IC 50 , of < 500 ng/ml), and three out of seven NTD-B mAbs having moderate neutralization potency (5,000-7,500 ng/ml) ( Fig. 2g-h) . Of the 10 convalescent donors, seven had at least one neutralizing mAb among the antibodies cloned for this study, although the potencies of the mAbs varied by donor (Fig. 2i ). Together, these data reveal that mAbs against the RBD are the predominate source of neutralizing antibodies induced by WT SARS-CoV-2 infection.

To understand the effects of viral variants on mAb binding to epitopes on the spike outside of the RBD, we tested non-RBD-targeting mAbs for binding to a panel of SARS-CoV-2 variants, including D614G and (Fig. 3h) . Although mAbs against NTD-A and S2 retain binding to VOCs, they are nonneutralizing, implying that NTD-A-and S2-reactive antibodies may provide limited immune pressure to mutate these epitopes. Of interest, NTD-B mAbs showed signi cantly reduced binding to the spike of B.1.1.7, B.1.351 and B.1.617.1 while showing similar binding to B.1.526 and A.23.1, and a minor reduction in binding to the spike of P.1 (Fig. 3h) . Two of the three neutralizing NTD-B binding mAbs (S166-32 and S305-1456), which were isolated from two different subjects, retained neutralization potential against B.1.1.7 and P.1 at moderate neutralizing potency (Fig. 3h) . The third neutralizing NTD-Bbinding mAb (S24-1301) also had moderate neutralizing potency against the WT strain with weak crossneutralization activity against the P.1 variant and no neutralization activity against B.1.1.7, consistent with its binding pro le (Fig. 3h) . However, all three neutralizing NTD-B mAbs failed to neutralize B. A subset of RBD-binding mAbs retain neutralization activity against VOCs Viral escape mutations occurring within the RBD may result in reduction in neutralization capacity of RBD-targeting antibodies [30] [31] [32] . To understand the impacts of RBD mutations on mAb binding, we tested RBD-targeting mAbs for binding to RBD mutants that possessed a single mutation found in circulating SARS-CoV-2 VOCs, VOIs, or arti cial mutants at key contact residues of the RBD-ACE2 interaction [30] [31] [32] [33] [34] [35] , as well as full-length spike constructs containing multiple mutations in the RBD (Supplementary Table 3 ). In addition, we tested mAb binding to the RBDs of SARS-CoV-1 and Middle Eastern Respiratory Syndrome (MERS)-CoV to investigate cross-reactivity to other coronaviruses. Notably, RBD-binding mAbs have been classi ed into four classes, classes 1-4 or receptor binding site (RBS) A-D, based on structural analysis and antibody binding features 36, 37 . More recently, classi cation of four key antigenic regions of the RBD can also be de ned by determining the loss of binding to RBD mutants (class 1-3 epitopes) or binding to cryptic epitopes on the RBD that are conserved across SARS-CoV-1 and MERS-CoV RBDs (class 4 epitope, Fig. 4a -b) 30, 38 . Based on the binding pro les of class 1-4 binding mAbs, we were able to segregate 23 out of 29 mAbs into one of the four classes ( Fig. 4c and Supplementary Figure 2b) . Notably, no class 1 mAbs were found and six mAbs could not be classi ed as they either lost binding to multiple mutant classes or bound equally to all RBD mutants but did not bind to SARS-CoV-1 or MERS-CoV.

Class 2 RBD-binding mAbs showed reduced binding to at least one of the RBD class 2 single escape mutants, notably E484K and F490K, and the majority of these mAbs lost binding to the RBD mutants found in the B.1.351, P.1, B.1.526 and B.1.617.1 (Fig. 4c ). Of the 12 class 2 mAbs, 11 were potently neutralizing against WT SARS-CoV-2. Of the neutralizing class 2 mAbs, all but one neutralized B.1.1.7 at concentrations comparable to neutralization of the WT strain. By contrast, six neutralized B.1.617.2 at lower potency compared to WT and B.1.1.7. Seven of the class 2 mAbs retained their neutralization activity against at least two VOCs (Fig. 4c) . Of note, 10 out of 11 neutralizing class 2 mAbs were unable to neutralize the variants that harbored a mutation at E484, P.1 and B.1.617.1. This is in line with previous studies, which have shown that the E484K and E484Q mutations are the key escaping residue responsible for neutralization resistance by P.1, P.2, B.1.351 and B.1.617.1 VOCs 2,4,39 . Of greatest interest, S144-1406, which retained binding to E484K and to all spike variants, neutralized B.1.1.7 and P.1 variants with high neutralization potency. Similar to another E484K-binder, S24-1224 neutralized three out of four VOCs tested, including B.1.617.1 (Fig. 4c) . These data indicate that some class 2 antibodies can crossneutralize VOCs. Additionally, the epitope targeted by S144-1406 partially overlapped with S24-1224 and other class 2 mAbs that failed to neutralize P.1 and B.1.617.1 (Supplementary Figure 2c) , suggesting class 2 mAbs target similar but slightly different RBD epitopes.

Only one mAb (S24-821) speci cally lost binding to the class 3 mutants, particularly to N439K and N440K, which are associated with circulating VOCs 35, 40 and have been reported as in vitro escape sites for class 3 epitope-binding mAbs 30, 31, 35 (Fig. 4b and Supplementary Table 3 ). Moreover, we classi ed ve more mAbs as class 3-like as they strongly competed for RBD binding with S24-821 but did not compete with class 2 mAbs (Supplementary Figure 2b) . Importantly, all class 3 and class 3-like mAbs maintained binding to L452R, another mutation associated with class 3 antibodies that is present in All of the mAbs that were categorized into class 4 (n=5) maintained binding to all RBD mutants and spike variants and displayed cross-reactivity to the SARS-CoV-1 RBD. However, all class 4 mAbs were nonneutralizing against WT virus, suggesting antibodies against this epitope are likely not strong drivers of antigenic drift. Notably, three antibodies in the class 4 group utilized the same heavy chain gene, VH5-51, as CR3022 and competed with CR3022 for binding to the RBD, indicating the class 4 antibodies in our study likely target the same or a similar epitope as CR3022 (Supplementary Table 2 and Supplementary  Figure 2d ). This is consistent with a previous study showing CR3022 cross-reacts with SARS-CoV-1, suggesting class 4 antibodies are common across subjects and studies 17, 30 .

With the classi cation of mAbs against distinct epitopes, we next tested the relative abundance of serum antibodies against these distinct epitopes of the RBD and NTD by performing competition assays. Notably, donors had signi cantly higher titers of serum antibodies targeting class 3 (S24-821) and class 3-like (S20-74) epitopes, whereas subjects largely had undetectable titers against class 2 and NTD-B epitopes, suggesting WT SARS-CoV-2 infection predominately induces polyclonal antibodies targeting RBD class 3 epitopes that can neutralize emerging VOCs B.1.1.7 and P.1. (Supplementary Figure 2e) . These data are consistent with the observed anti-B.1.1.7 and anti-P.1 serum neutralizing titers shown in Fig. 1c , suggesting the retention of serum neutralization activity could be due to abundant class 3 antibody responses. Loss of neutralization capabilities to B.1.617-lineage viruses may be due to insu cient levels of class 2 serum antibodies. A comparison of the neutralization capabilities of mAbs targeting different epitopes revealed class 2 RBD-reactive mAbs were the most potently neutralizing followed by mAbs targeting class 3 RBD epitopes and NTD-B (Supplementary Figure 3a) . It is important to note that none of neutralizing mAbs induced by natural WT infection were able to neutralize all emerging SARS-CoV-2 variants. Nonetheless, we identi ed at least one mAb that could neutralize each VOC, suggesting the convalescent donors generated a diverse cross-neutralizing antibody response (Supplementary Figure 3b) . Therefore, antibodies targeting multiple epitopes on the spike are a valuable source of neutralizing antibodies against emerging VOCs. Moreover, the cross-neutralizing RBD-targeting mAbs used V(D)J gene features similar to other published RBD-binding mAbs (Supplementary Table 3) [42] [43] [44] . However, the mAbs in our studies utilized distinct heavy and light chain pairings, indicating these clones are not public with other known neutralizing SARS-CoV-2 antibodies. Despite this, our data indicate that cross-neutralizing antibodies use a diverse antibody repertoire against multiple distinct epitopes. Therefore, driving a polyclonal antibody response against these three epitopes may provide cross-neutralizing protection against existing and future variants.

Our study shows WT SARS-CoV-2-convalescent individuals possess antibodies that can effectively crossneutralize against emerging VOCs, with cross-neutralizing antibodies targeting multiple epitopes of the spike protein. In total, we identi ed 12 mAbs that potently neutralize current circulating VOCs, including B.1.1.7, the alpha variant that has been reported to be more infectious 8, 19 , P.1, the gamma variant that partially escapes both natural and vaccine-induced humoral immunity 2,12,45 , and B.1.617.2, the delta variant that is more transmissible than the alpha variant and has led to a surge of more hospitalizations in India and can evade partial immunity induced by one vaccine dose 4, 15, 23 . Convalescent subjects in our cohort had su cient serum titers to neutralize both B.1.1.7 and P.1 but not B.1.617, suggesting that the cross-neutralizing mAbs identi ed in this study may play an important role in polyclonal neutralization for some of VOCs.

Using high-throughput antigen probing at the single B cell level, we found that B cells isolated from convalescent subjects largely targeted non-RBD epitopes rather than potently neutralizing epitopes on the RBD. Similarly, mRNA vaccines also largely induce antibodies against non-neutralizing epitopes, suggesting epitopes outside of the RBD are immunodominant 46 . Despite this, vaccination has been shown to induce cross-neutralizing antibodies 1 , suggesting both natural WT infection and currently approved vaccines can elicit protective humoral immunity against emerging variants. As we identi ed 12 antibodies cross-neutralizing to VOCs derived from seven different convalescent COVID-19 donors, our study suggests most people generate a cross-neutralizing antibody response. Notably, these antibodies largely target three distinct epitopes, including two sites on the RBD and the one on the NTD. Several recent studies have demonstrated that antibodies against the NTD and S2 are neutralizing [47] [48] [49] . Although the anti-S2 mAbs identi ed in our study were non-neutralizing, S2-binding antibodies exhibit broad reactivity with spike proteins from SARS-CoV-2 variants, related betacoronaviruses such as SARS-CoV-1 and MERS-CoV, and distantly related endemic coronaviruses. Moreover, anti-spike serum antibodies can mediate protection via Fc-mediated functions, suggesting a combination of neutralizing antibodies and polyfunctional antibodies will provide optimal protection against infection with variants of SARS-CoV-2 50 .

Our study also showed that anti-RBD mAbs are primarily class 2 mAbs, consistent with other reports 30, 37, 43, 51 . The majority of class 2 mAbs retained their neutralization activity against B.1.1.7 and B.1.617.2, but were largely non-neutralizing against P.1, suggesting class 2 mAbs may have driven the evolution of P.1 mutants. In contrast, neutralizing class 3 mAbs retained their neutralization activity against both B.1.1.7 and P.1, but did not neutralize the B.1.617 variants. Notably, none of the neutralizing mAbs could cross-neutralize B.1.1.7, P.1 and B.1.617.2, the most prevalent VOCs at this time. Therefore, vaccination approaches to increase a nity and frequencies of antibodies to the S1 domain may enhance the breadth of protection against emerging SARS-CoV-2 VOCs, including epitopes on the RBD and NTD. It is likely that targeting multiple epitopes will provide optimal protection so as to avoid generating escape mutants that can evade antibodies against any one epitope. Moreover, vaccinating previously infected subjects has been shown to substantially improve neutralization titers 3 and may allow for re nement of memory B cells against neutralizing epitopes.

In conclusion, our study shows SARS-CoV-2 infection induces cross-neutralizing immunity against circulating VOCs, which is likely attributed to polyclonal antibodies targeting multiple epitopes of the spike protein. This work emphasizes the need for the induction of cross-neutralizing antibodies that bind distinct sites on the spike with various mechanisms that can synergize to provide protection against SARS-CoV-2 variants as well as limit the virus from escaping any single antibody target.

All studies were performed with the approval of the University of Chicago institutional review board IRB20-0523 and University of Chicago, University of Wisconsin-Madison. Informed consent was obtained after the research applications and possible consequences of the studies were disclosed to study subjects. This clinical trial was registered at ClinicalTrials.gov with identi er NCT04340050, and clinical information for patients included in the study is detailed in Extended Data Table 1 . The details of PBMC collection from leukoreduction lters were described elsewhere 27 . For spike-speci c B cells sorting, PBMC were thawed in 37℃ water bath and B cells were enriched using human pan B cell EasySepTM enrichment kit (STEMCELL). B cells were stained with anti-CD19-PE-Cy7 (Biolegend) and anti-CD3-BV510 (BD Biosciences) and antigen probes (PE) for 30 minutes on ice in 1X PBS supplemented with 0.2% BSA and 2 mM Pierce Biotin. Probe generation was performed as previously described 27 . Cells were subsequently washed with 1X PBS with 0.2% BSA and stained with Live/Dead BV510 (Thermo Fisher) in 1X PBS for 15 minutes. Cells were washed again and re-suspended at a maximum of 4 million cells/mL in 1X PBS supplemented with 0.2% BSA and 2 mM Pierce Biotin for downstream cell sorting using the MACSQuantTyto cartridge sorting platform (Miltenyi). Viable/CD19+/antigen-PE+ cells were sorted as probe positive. Cells were then collected from the cartridge sorting chamber and used for downstream processing with the chromium controller (10X Genomics).

The human B cell V(D)J, 5' gene expression, feature barcode libraries were prepared according to manufacturer's instructions. Libraries were pooled and sequenced using an Illumina NextSeq550 or an Illumina NextSeq 500 at the University of Chicago. Cell Ranger (version 3.0.2) was used to perform raw sequencing processing, sample de-multiplexing, barcode processing, single-cell 5' transcripts counting and B cell receptor repertoire sequences assembly. The reference genome assembly for transcriptome is GRCh38-1.2.0, and reference genome assembly for V(D)J is cellranger-vdj-GRCh38-alts-ensembl-2.0.0. The data obtained from Cell Ranger were subsequently performed downstream analysis using Seurat toolkit (version 3.2.0, an R package, for transcriptome, cell surface protein and antigen probe analysis) 52 and IgBlast (version 1.15) for immunoglobulin gene analysis 53 . Cell quality control (QC), normalization, data scaling, and linear dimensional reduction, clustering, differential expression analysis, batch effects correction, and data visualization were processed using Seurat (version 3.2.0). The QC of cells were performed further to exclude cells with less than 200 and more then 2500 detected genes and cells expressing high percentage of mitochondrial genes. Transcriptome RNA data was analyzed using conventional log normalization. We performed principal component analysis (PCA) and used the top 15 principal components (PCs) in linear dimensional reduction and clustering. Only ltered, high-quality cells were clustered in this analysis using Louvain algorithm implemented in Seurat under the resolution of 0.6 for clustering. Batch effects across different datasets were normalized using an Anchor method implemented in Seurat.

Monoclonal antibody production B cells were selected for mAb generation based on antigen probe intensity visualized by JMP Pro 15, as previous described 27 . Antibody heavy and light chain genes obtained by 10X Genomics V(D)J sequencing analysis were synthesized by Integrated DNA Technologies. The synthesized fragments for heavy and light chain with 5' and 3' Gibson overhangs were then cloned into human IgG1 and human kappa or lambda light chain expression vectors by Gibson assembly as previously described 54 . The heavy and light chains of a corresponding mAb were co-transfected into HEK293T cells. After 4 days, secreted mAbs in the medium supernatant were harvested and puri ed using protein A agarose beads (Thermo Fisher).

The recombinant WT SARS-CoV-2 full-length (FL) spike, D614G FL spike, WT RBD, K417T/R/A RBD, N501Q/A RBD, and SARS-CoV-1 RBD and MERS-CoV were generated in-house either by using gBlock fragment synthesized by Integrated DNA Technologies or by performing single-site mutagenesis, and expressed by Expi293F cells (Thermo Fisher). The recombinant FL spikes derived from variants of B. 1.1.7, B.1.351, P.1, B.1.526, B.1.617.1 and A. 23.1 were kindly provided by Dr. Noah Sather laboratory at Seattle Children's Research Institute. The recombinant RBD found in VOCs, B.1.351 or P.1 variants, and RBD with single mutation or multiple mutations (N439:Y453F, E406Q, K417E, K417V, Y453F, F486A, N487R, F490K, Q493R, N439K, N440K, N501Y) were generously provided from the Krammer laboratory at Icahn School of Medicine at Mount Sinai. The recombinant S1 and S2 subunit, and RBD with single mutation of K417N, E484K and L452R were obtained from Sino Biological. The protein sequences and resources for each antigen are listed in Extended Data Table 3 .

Virus neutralization assays were performed with different variants of SARS-CoV-2 on Vero E6/TMPRSS2 (Extended Data Table 4 ). Virus (~100 plaque-forming units) was incubated with an equal volume of twofold diluted of serum or mAbs for 1 hour. Plasma samples were diluted in calcium free media, while antibodies were diluted in growth media. In addition, plasma was heat treated for 30 minutes at 37 ℃ prior to use. The antibody/virus mixture was added to con uent Vero E6/TMPRSS2 cells that were plated at 30,000 cells per well the day prior in 96-well plates. The cells were incubated for 3 days at 37 °C and then xed and stained with 20% methanol and crystal violet solution. Virus neutralization titers were determined as the reciprocal of the highest serum dilution that completely prevented cytopathic effects.

The 50% inhibitory concentrations for mAbs (IC50) was determined using log(inhibitor) versus normalized response (variable slope) performed by Prism (Graphpad Version 9.0). All plasma and mAbs were tested in duplicate and each experiment was performed twice.

High-protein binding microtiter plates (Costar) were coated with 50 μl of recombinant proteins (either fulllength spike or RBD) at 2 μg/ml in 1×PBS solution overnight at 4℃. The plates were washed 3 times the next day with 1×PBS supplemented with 0.05% Tween 20 and blocked with 175 μl of 1×PBS containing 20% FBS for 1 hour at 37℃. MAbs were serially diluted 1:3 starting at 10 μg/ml and incubated for 1 hour at 37℃. The plates were then washed 3 times and incubated with horseradish peroxidase (HRP)conjugated goat anti-human IgG antibody (Jackson ImmunoResearch) diluted 1:1000 for 1 hour at 37℃, and plates were subsequently developed with Super AquaBlue ELISA substrate (eBioscience).

Absorbance was measured at 405 nm on a microplate spectrophotometer (Bio-Rad). To standardize the assays, control antibodies with known binding characteristics were included on each plate and the plates were developed when the absorbance of the control reached 3.0 OD405 units. All mAbs were tested in duplicate and each experiment was performed twice.

To determine the classi cation of certain mAbs, competition ELISAs were carried out using the mAbs with known epitope binding property as competitor mAbs. The competitor mAbs were biotinylated overnight at 4℃ with EZ-LinkÔ Sulfo-NHS-Biotin (Thermo Scienti c). The excess free biotin of biotinylated mAbs were removed by 7k MWCO ZebaÔ spin desalted columns (Thermo Scienti c). Plates were coated with 50 μl of 2 μg/ml RBD antigen overnight at 4℃. After 1 hour of blocking the plates with PBS 20% FBS, the 2-fold dilution of undetermined class mAbs or serum were added (starting at 20 μg/ml of mAbs and 1:50 of serum) into coated well. After incubated for 2 hours at room temperature, biotinylated competitor mAb was added at a concentration of 2x K d and incubated another 2 hours at room temperature together with mAbs or serum that were previously added. The plates were washed 3 times and incubated with 100 μl HRP-conjugated streptavidin (Southern Biotech) dilution of 1:1000 for 1 hour at 37℃. The plates were developed with Super AquaBlue ELISA substrate (eBioscience). To standardize the assays, competitor biotinylated mAb was added in well that without any competing mAbs or serum as control well. The data were recorded when the absorbance of the control well reached 1 to 1.5 OD405 units. All mAbs were tested in duplicate and each experiment was performed twice. The percent competition was then calculated by dividing a sample's observe OD by the OD reached by the positive control, subtracting this value from 1, and multiplying by 100. For the serum data, ODs were log transformed and analyzed by non-linear regression to determine EC50 values using Prism software (Graphpad Version 9.0).

To determine the classi cation of certain mAbs, competition assays were performed using the mAbs with known epitope binding property as competitor mAbs with mAb binding unknown epitopes using BLI with a Octet K2 instrument (Forte Bio). The RBD of SARS-CoV-2 was biotinylated, desalted and loaded at a concentration of 10 μg/ml onto streptavidin probes for 300 seconds followed by PBS for 60 seconds. The probe was moved to associate with mAbs of interest (10 μg/ml) for 300 seconds followed by PBS for 60 seconds and then associations with control mAbs (10 μg/mL) for 300 seconds. The nal volume for all the solutions was 200 ml/well. All of the assays were performed with PBS buffer at 30℃. SARS-CoV-2 Spike and RBD protein models FL mutations were visualized on the WT spike protein (PDB: 7KJ2) using PyMOL (Schrödinger). The model of RBD mutations and RBD classes were visualized on the WT RBD protein (PDB: 7KDL) using PyMOL (Schrödinger). The models were further processed by Adobe Illustrator 2021 and Adobe

Photoshop.

All statistical analyses were performed using Prism software (Graphpad Version 9.0). Sample sizes (n)

for the number of mAbs tested are indicated in corresponding gures or in the center of pie graphs. Number of biological repeats for experiments and speci c tests for statistical signi cance used are indicated in the corresponding gure legends. P values less than or equal to 0.05 were considered signi cant. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P < 0.0001.

We kindly thank the University of Chicago CAT Facility (RRID: SCR_017760) and University of Chicago Genomics Facility (RRID: SCR_019196) for assisting in sorting and sequencing samples. 

Several mAbs generated from this work are being used by Now Diagnostics in Springdale, AR for the development of a diagnostic test. The University of Chicago has led a patent application relating to anti-SARS-CoV-2 antibodies generated in previous work 27 with P.C.W., H.L.D., and C.T.S. as co-inventors. The Icahn School of Medicine at Mount Sinai has led patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Fatima Amanat is also listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and P zer (before 2020), and is currently consulting for P zer, Seqirus and Avimex. The Krammer laboratory is also collaborating with P zer on animal models of SARS-CoV-2. Characterization of spike-reactive mAbs. a, b, Uniform manifold approximation and projection (UMAP) of SARS-CoV-2 spike non-RBD binding (a) and spike RBD binding B cells (b) isolated from the PBMCs of 10 convalescent subjects. c, The proportion of spike non-RBD and spike RBD speci c binding B cells. The number in center of pie chart indicates the number of antigen-speci c binding B cells. d, mAbs generated from selected B cells (n=43) were tested for binding to full-length spike, S1, S2, and RBD and Binding and neutralization pro les of RBD-binding mAbs against a panel of RBD escape mutants and variants. a, Structural model of RBD "up" binding with ACE2 (a; PDB: 7KJ2) and RBD antibody classes and associated escape mutants. b, RBD is colored by antibody classes and associated mutations: class 1 (pink), overlapping of class 1 and 2 (purple), class 2 (blue), class 3 (teal). c, Heatmap detailing binding reactivity of RBD mAbs (n=29) against single key escape sites for class 1, class 2 and class 3 antibodies,

E cacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England

Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England

A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identi ed in New York. medRxiv

Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation

Sixteen novel lineages of SARS-CoV-2 in South Africa

Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B. 1.617. 1 variant

Structural basis of receptor recognition by SARS-CoV-2

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccineinduced sera

The variant gambit: COVID-19's next move

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

SARS-CoV-2 variants of concern are emerging in India

COVID-19 weekly epidemiological update

Effectiveness of COVID-19 vaccines against the B. 1.617. 2 variant. medRxiv

SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion

A SARS-CoV-2 lineage A variant (A. 23.1) with altered spike has emerged and is dominating the current Uganda epidemic

SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike

Pro ling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Potently neutralizing and protective human antibodies against SARS-CoV-2

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. bioRxiv

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Structural basis of a shared antibody response to SARS-CoV-2

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

Circulating SARS-CoV-2 spike N439K variants maintain tness while evading antibody-mediated immunity

Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv

Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants. bioRxiv

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Viral epitope pro ling of COVID-19 patients reveals cross-reactivity and correlates of severity

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic e cacy of the antibody

Potent Neutralizing Antibodies against SARS-CoV-2 Identi ed by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Comprehensive Integration of Single-Cell Data

IgBLAST: an immunoglobulin variable domain sequence analysis tool

An E cient Method to Generate Monoclonal Antibodies from Human B Cells

Number in the center of pie graphs indicate the number of antibodies tested. g, Comparison of neutralizing capability of mAbs targeting spike RBD and spike non-RBD. h and i, IC50 of neutralization potency of spike-reactive antibodies against WT virus based on domain speci city (h) and by subject (i). Mean in h indicated as a solid line

Genetic characterization of each mAb is further detailed in Extended Data Table 2. combinations of RBD mutants, and RBD from SARS-CoV-1 and MERS-CoV. Abbreviation of a refers to class-3 like antibodies

The panel of recombinant antigens in c are detailed in Extended Data Table 3, including mutations found in circulating SARS-CoV-2 variants (bold), the mutations that escape/reduce binding by polyclonal serum/potent neutralizing mAbs (italic), the mutations found in both circulating SARS-CoV-2 variants and in vitro escape-map (bold+italic), and arti cial mutants at key contact residues of the RBD-ACE2 interaction (normal typeface). The neutralization potency (IC50) of spike-RBD mAbs against WT

Data in c are representative of two independent experiments performed in duplicate. Genetic information